The Low DoseThe GLP-1 price desk
Briefing

Fifty 410 vs Coby Health

$133/mo against $239/mo for tirzepatide. Which is worth it, and for whom.

Illustration of two objects on a balance scale

Updated 2026-09-18

Both sell tirzepatide. Fifty 410 costs $133 a month and Coby Health costs $239, a difference of $106 a month or about $1,272 a year. The desk reads it as follows.

Fifty 410 is prepaid blocks with no subscription. Coby Health is multi-month value with supplies included. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.

Advert against bill. Fifty 410 advertises $133 and bills $133; Coby Health advertises $179 and bills $239. The gaps are different sizes, which means comparing the two on their advertised prices gives you the wrong answer.

Side by side

Fifty 410Coby
Advertised$133$179
Billed$133$239
Gapnone+$60
Per year, billed$1,596$2,868

Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.

The split

1 differences on the record. The others match.

Fifty 410Coby
Month-to-month without prepaying a blockNoYes

What each puts on the record: Fifty 410

  • Provider consultation and free 1-2 day shipping included in the price.
  • States it is a telehealth platform that does not compound or distribute medication itself, and that preparations come from FDA-registered 503A pharmacies.

Where it wins: Genuinely no subscription — you buy a block and nothing recurs. Watch for: The $133 is the starter protocol. Moving to the high-dose protocol takes it to $183/month, and both are prepaid three-month commitments.

What each puts on the record: Coby Health

  • Monthly plans can be cancelled at any time.
  • States plainly on its own product pages that compounded medication is not FDA-reviewed or approved.

Where it wins: Injection supplies are included rather than something you source yourself. Watch for: The $179 figure is a multi-month rate. Month-to-month is $239.

In each one’s favour

Fifty 410.

  • Genuinely no subscription — you buy a block and nothing recurs.
  • Among the lowest tirzepatide rates verified.

Coby Health.

  • Injection supplies are included rather than something you source yourself.
  • Monthly plan is genuinely cancel-anytime.

Fifty 410 scores higher overall at 4.2 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.

The desk’s call

The board says Fifty 410. What the board cannot say is whether the advertised figures you were shown elsewhere match these — check the gap row, because a listing that advertises low and bills high will beat an honest one in any comparison built on advertised prices.

The verdict

On the board, Fifty 410 at $133 a month is the more defensible choice on arithmetic alone. Coby Health earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: Fifty 410 and Coby Health.

How they sit against everyone else

ProgrammeAdvertisedBilledGapVs board floor
Coreage Rx$149$199+$50+$74/mo
Trimi$125$125none—
Ozari Health$125$125none—
Fifty 410$133$133none+$8/mo

More from the desk

  • Fifty 410 tirzepatide review

    Advertised at $133 and billed at $133 — no gap. Position 4 of 18 on our board.

  • Coby Health tirzepatide review

    Advertised at $179, billed at $239. Position 9 of 18 on our board.

  • How to spot a bad seller

    The FDA sent more than 55 warning letters to online GLP-1 sellers in one day. Here is how to tell a licensed programme from the rest.

  • The twelve-month cost

    Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.

  • Cheapest right now

    Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.

Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure